Search Bar & Filters
Found 97 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of delgocitinib cream 20 mgg applied twice daily compared to a non-active cream vehicle in treating adults with mild to severe palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This phase 2a, double-blind study aims to provide proof-of-concept evidence over a 16-week treatment period. Participants will be randomly assigned to one of two groups one group will apply delgocitinib cream twice daily, and the other will apply a matching vehicle cream twice daily for 16 weeks. The study includes approximately 9 visits over about 18 weeks in total, covering treatment and follow-up periods. Throughout the trial, participants will attend scheduled visits for assessments including skin evaluations, photography confirmation of PPP, and various symptom and quality of life measures. Researchers will monitor improvements using the PPP Area and Severity Index PPPASI and Physician Global Assessment PGA, as well as track adverse events and changes in symptoms like itch and pain. The main outcome is the number of participants achieving at least a 75% improvement in PPPASI score after 16 weeks of treatment.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are investigating new treatments for advanced, high-grade ovarian cancer, including cancers that started in the ovaries, lining of the belly, or fallopian tubes. This trial focuses on participants whose cancer has spread and is difficult to remove surgically. The study compares a new medicine called raludotatug deruxtecan R-DXd, given with or without bevacizumab, to standard platinum-based chemotherapy with or without bevacizumab. The main goal is to see if R-DXd helps participants live longer and delay cancer growth compared to current treatments. Participants will be randomly assigned to receive either R-DXd intravenously with or without bevacizumab, or standard chemotherapy options including carboplatin, paclitaxel, gemcitabine, or pegylated liposomal doxorubicin, with or without bevacizumab. Treatments may continue for up to 2 years or until the cancer worsens or side effects prevent further treatment. Bevacizumab, if used, will be given every three weeks alongside the other therapies. During the trial, participants will have regular assessments to monitor cancer progression and overall survival for up to approximately 3 to 4 years. Researchers will track side effects, treatment responses, quality of life, and other health measures. Participants will undergo various evaluations including imaging, questionnaires, and lab tests to carefully observe their health and treatment effects throughout the study period.
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
This research aims to evaluate the long-term safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis who have already completed treatment in a prior APG777 study. The study is a multicenter, double-blind, phase 2 extension designed for participants who, according to the investigator, could benefit from continued APG777 treatment. The study consists of three periods a Screening Visit coinciding with the last visit of the parent studys Maintenance Period an Extended Treatment Period where participants maintain their APG777 dose from the previous study or receive open-label APG777 if they did not meet certain response criteria and a Post-treatment Follow-up Period. Participants receive APG777 as subcutaneous injections every 12 or 24 weeks, depending on their previous dosing regimen or study arm assignment. During the study, participants will have assessments for safety and efficacy, including monitoring treatment-emergent adverse events for up to 3 years. Researchers will also track improvements in eczema severity, itch symptoms, use of rescue therapy, and serum drug concentrations over an average of 2 years during the Extended Treatment Period. Participation may last up to 3 years, including follow-up to observe long-term outcomes.
Actively Recruiting
Researchers are evaluating how well the medicine zasocitinib works and its safety in children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis. The study is conducted in two parts Part A includes both children and teenagers, while Part B includes only children. Initially, only teenagers meeting specific study rules can join, with children joining after sufficient data is available from other studies. In Part A, participants are randomly assigned to receive either zasocitinib or a matching placebo orally once daily for the first 16 weeks. After this, all receive zasocitinib until the study ends. In Part B, all children receive weight-based oral doses of zasocitinib throughout the study. The treatment lasts up to 208 weeks, with a total study participation time of up to 217 weeks, including screening and safety follow-up. Participants will visit the study site multiple times during the study for assessments, including skin evaluations and measuring drug levels in the blood. Researchers will monitor how well participants respond using various psoriasis severity scales and quality of life questionnaires. A safety follow-up period of 4 weeks occurs after treatment ends to monitor any ongoing effects. The study aims to understand zasocitinibs effects and safety in this young population over a long term.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating a combination therapy of ruxolitinib, steroids, and lenalidomide in adults with relapsed or refractory multiple myeloma MM who have progressive disease despite previous treatments. MM is a cancer of plasma cells in the bone marrow with complex causes and limited curative options. This phase 1, open-label, multicenter study aims to assess the safety and effectiveness of these drugs together in patients who have failed at least two prior therapies including immunomodulatory drugs and proteasome inhibitors. Participants receive varying doses of ruxolitinib orally twice daily, lenalidomide once daily, and methylprednisolone every other day. The study includes dose escalation periods and treatment adjustments based on disease progression. Some groups start with ruxolitinib and steroids, adding lenalidomide only if the disease worsens. Treatment continues until disease progression or unacceptable side effects occur. During the study, participants will have regular evaluations including blood tests and clinical assessments to monitor safety, side effects, and treatment response. Researchers will measure outcomes such as the maximum tolerated dose, adverse events, response rates, progression-free and overall survival over a follow-up period extending up to 54 months. Participants are expected to adhere to visit schedules and study requirements throughout the trial.
Actively Recruiting
Researchers are evaluating XL309 previously ISM3091, alone and in combination with olaparib, in participants with advanced solid tumors. This first-in-human, multicenter, open-label Phase I trial aims to assess the safety, tolerability, preliminary antitumor activity, as well as how the body processes and responds to XL309 in these patients. The study is sponsored by Exelixis and targets advanced cancers that have progressed despite standard treatments or have no current therapies available. The study includes a Dose Escalation Stage where participants receive increasing doses of XL309 alone or combined with olaparib. Following this, a Cohort Expansion Stage will further study the recommended dose in specific advanced solid tumor groups both as a single agent and in combination. Both drugs are given orally according to assigned schedules in sequential cohorts. The trial is non-randomized and open-label, meaning all participants know which treatment they are receiving. Participants will undergo safety monitoring for treatment-related adverse events, dose-limiting toxicities, and laboratory abnormalities over approximately 24 months. Researchers will also measure drug levels in the blood and tumor response rates. Eligibility includes adults with specific genetic alterations related to their cancer type, adequate organ function, and performance status. The study excludes those with recent anticancer treatments, untreated brain metastases, or certain health conditions. Participants may be followed for up to several years to evaluate safety and preliminary efficacy.
Actively Recruiting
Researchers are evaluating the safety, dosage, and preliminary antitumor effects of Pocenbrodib alone and combined with darolutamide in men with metastatic castration-resistant prostate cancer mCRPC who have progressed after prior therapies including potent anti-androgen treatments. This Phase 1b2a open-label study includes dose escalation and optimization to find the maximum tolerated dose and recommended Phase 2 doses of Pocenbrodib, both as monotherapy and in combination with darolutamide. The study has three arms in Phase 1b Pocenbrodib given once daily 5 days on2 days off, Pocenbrodib given twice daily continuously, and Pocenbrodib combined with darolutamide twice daily continuously as a safety run-in for combination therapy. Phase 2a further evaluates the combination in two cohorts receiving different recommended doses of Pocenbrodib plus darolutamide after progression following lutetium-Lu-177-vipivotide-tetraxetan PLUVICTO and before taxane chemotherapy. Safety is closely monitored throughout. Participants will undergo assessments including safety and tolerability checks, pharmacokinetic and pharmacodynamic measurements, and evaluations of antitumor activity over treatment cycles of 28 days, estimated up to six months. Laboratory tests, imaging, and prostate-specific antigen PSA measurements will be collected to assess responses. Monitoring for adverse events and dose optimization guides treatment throughout the study duration until disease progression or discontinuation.
1-10 of 97
1